Product Description
for the Treatment of ALpha-1 ANTitrypsin Deficiency. Alvelestat (MPH966, formerly AZD9668) is a potent, selective, and reversible, oral inhibitor of human NE. Suppression of NE is expected to reduce lung damage and may slow disease progression. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03679598)
Mechanisms of Action: ELA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Orphan Drug - alpha 1-Antitrypsin Deficiency *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Emphysema|alpha 1-Antitrypsin Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ATALANTa | P2 |
Completed |
Chronic Obstructive Pulmonary Disease|Emphysema|alpha 1-Antitrypsin Deficiency |
2023-11-30 |
50% |
2023-12-16 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/05/2025 |
News Article |
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference |
|
01/07/2025 |
News Article |
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
|
11/14/2024 |
News Article |
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference |
|
09/12/2024 |
News Article |
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference |
|
04/02/2024 |
PubMed |
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. |
|
09/15/2022 |
PubMed |
Novel benzoxazinone derivative as potent human neutrophil elastase inhibitor: Potential implications in lung injury. |
|
08/10/2022 |
PubMed |
Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. |